ACE2 and COVID-19: To evaluate the ability of antibodies to RBD or RBM436-507 sequences to block ACE2 binding to RBD, specific anti-RBD and anti-RBM436-507 antibodies were eluted from COVID-19 positive sera using antigen-coated wells and incubated with labeled ACE2 on solid-phase RBD.